New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
16:09 EDTAMRIAMRI closes Cedarburg deal, sees adding 6c-7c to FY14 adjusted EPS
AMRI announced that it has completed the previously announced acquisition of Cedarburg Pharmaceuticals. Total consideration paid was $41M, including assumption of certain liabilities. AMRI financed the transaction with cash on hand. The acquisition is expected to add between $13M-$14M to AMRI's revenue in FY14. AMRI anticipates full year run-rate synergies of approximately $1.5M of EBITDA within 12 months of closing and the acquisition is expected to be accretive to AMRI's FY14 adjusted diluted EPS in the range of 6c-7c per share.
News For AMRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 13, 2015
07:42 EDTAMRIJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
January 12, 2015
08:36 EDTAMRIAMRI announces development and supply agreements with Genovi Pharma
Subscribe for More Information
08:31 EDTAMRIAMRI announces the departure of CFO Michael Nolan
AMRI announced that Michael Nolan, senior vice president and CFO, will be departing AMRI. Nolan will remain with AMRI through February 2015 to support an orderly transition. The company also announced that Felicia Ladin will join the company in the same role, effective February 4, 2015. Ladin most recently served as Senior Vice President, CFO, Global Specialty Medicines at Teva (TEVA).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use